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1.1. Non-coding RNAs in the Human Genome: 
 
Before the completion of the Human Genome Project, the genome was expected to contain at least 
100,000 protein coding genes. The sequencing, however, revealed that only about 21,000 such genes 
can be found within the approximately 3 billion DNA bases. Although approximately 76% of the 
human genome is transcribed, less than 3% encodes for proteins. [1] 
 
The remaining 97% were thought to be “junk” DNA as these sequences are not translated into protein 
and were not known to encode relevant information with the exception of few non-coding RNAs such 
as transfer or ribosomal RNAs. This assumption was based on the central dogma of molecular biology 
postulated by Francis Crick in 1958, which states that all relevant biological information flows 
unidirectionally from DNA to mRNA to protein. [2, 3] [4] 
 
As the number of protein coding genes was unexpectedly low and similar to much simpler organisms, 
it was not immediately clear how the high degree of human complexity could derive from such a 
small protein repertoire. Additionally, the proteomes of higher organisms have been shown to be 
relatively stable, with humans and mice sharing 99% of their protein coding genes. Although 
mechanisms like alternative splicing can increase the variation of the protein repertoire, today the 
complexity of the regulatory network of non-coding RNAs, i.e. the control architecture of the system, 
is thought to be a main source of diversity. [5] [6] 
 
This is supported by the fact that while there is only a small increase in the number of  protein coding 
genes in humans as compared to the nearly 19,000 protein coding genes in the nematode C. elegans, 
the ratio of non-protein coding to protein coding sequences is almost 17-fold higher in humans. [6] [7] 
MicroRNAs (miRNAs) represent one subgroup of non-coding RNAs. More than 2000 miRNAs are 
encoded in the human genome, but only about 400 miRNAs can be found in C. elegans. [8]  The 
miRNA system is also highly evolutionary conserved: 196 miRNA families are conserved among 
mammals and 34 miRNA families from C. elegans are conserved in humans with few examples of 
secondary loss and very low levels of nucleotide substitutions to the primary sequence. [9, 10] 
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1.2. The Role of MiRNAs: 
 
Epigenetic control mechanisms including miRNAs, that temporarily modulate gene expression, allow 
the cell to respond quickly to environmental changes as miRNA molecules can be directly produced 
from DNA and are easily degraded. [11] 
 
MiRNAs are one of the largest gene families and account for ~1% of the human genome, which is 
quite remarkable considering that about 3 % of the genome are coding for proteins. [12] Due to their 
mode of operation, they have the potential to target approximately 60% of all human genes and 
thereby influence almost all genetic pathways. [13] [14] MiRNAs are expressed in a temporal and 
tissue-specific manner [15], e.g. miR-208a can only be found in cardiomyocytes [16] and the miRNA 
content in different cells can vary from 1 to more than 30,000 copies. [17] MiRNAs play an important 
role in the regulation of embryonic development as well as in adult life with distinct expression 
profiles in every cell type at each developmental stage. [18] They show dynamic and site specific 
expression patterns during embryogenesis and suppression of these genes leads to death during early 
gestation. [19] [20] 
 
 
1.3. History of MiRNAs: 
 
The first miRNA was identified in 1993 during the study of C. elegans mutants that exhibited 
abnormal developmental timing. The gene responsible for this phenotype, lin-4, did not code for a 
protein but for two small RNAs with complementary sequences to the 3’-untranslated region of the 
lin-14 mRNA. Lin-4 had been shown previously to negatively regulate the protein level of LIN-14, 
creating a temporal decrease in LIN-14 during postembryonic development that regulates the 
execution of stage specific larval programs. [2, 21, 22]  
A similar mechanism of RNA silencing had been known in plants since the beginning of the 1990s 
[23] but as lin-4 was not detected in other species, this new mechanism was believed to be a process 
occurring only in nematodes. However, in the year 2000, a similar non-coding RNA, let-7, that also 
coordinates developmental timing in C. elegans was discovered. Let-7 codes for a 21 nucleotide non-
coding RNA transcript that negatively regulates the mRNA of lin-41 through complementary Watson-
Crick base pairing at the 3’-UTR and therefore influences gene expression in a way similar to lin-4. 
[20] Unlike lin-4, the sequence of let-7 was found to be conserved in a wide range of species 
including vertebrates, making the biological significance of this finding apparent. [24] [4] Since then, 
over 25,000 miRNAs have been identified from more than 190 different species including algae, 
plants, nematodes, protozoa, viruses or vertebrates. [4]  
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1.4. Biogenesis and Function of MiRNAs: 
 
 
 
 
Figure 1 Mechanism of miRNA biogenesis. Taken from [25] 
 
MiRNA genes are located in different parts of the human genome, and hence show a great variation in 
their transcriptional regulation and expression patterns. [26] The majority of human miRNAs are co-
expressed together with their host gene within intronic sequences of protein-coding genes, while 
others are transcribed independent of coding genes. [14]  More than 40% of human miRNAs appear in 
clusters and are transcribed together, forming a transcript that contains multiple miRNA 
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sequences.[27] After transcription by mainly RNA polymerase II [28], the pri-miRNA is processed by 
the RNaseIII Drosha, into a stem-loop precursor of ~70 nucleotides, the so called pre-miRNA [29]. 
As Drosha by itself cannot bind pri-miRNAs sufficiently, it acts together with the cofactor DGCR8, 
together forming the microprocessor complex. [30] The pre-miRNA is then exported to the cytoplasm 
in a Ran-GTP dependent way by Exportin-5 that specifically binds the pre-miRNA. [31] Once it has 
reached the cytoplasm, the pre-miRNA is cleaved by the RNaseIII Dicer together with the cofactor 
TRBP [32] [33] and PACT [34] into a duplex, consisting of two miRNA strands. [35] After 
transcription the individual miRNAs can be additionally regulated by adenosine deaminases that 
convert adenosine to inosine and thereby influence the hybridisation of miRNAs to their targets.  [36] 
The RNA duplex is subsequently loaded onto an Argonaute protein together forming the RNA-
induced silencing complex (RISC). After the duplex has been unwinded one of the strands is released 
and in most cases degraded. The other strand guides the RISC to miRNA response elements (MRE) of 
the target gene that are complementary to its sequence. [4] [9]  MiRNAs mainly target mRNAs, but 
also have the potential to bind to a wide variety of other molecules including tRNAs or rRNAs. [37] 
Each miRNA locus therefore produces two mature miRNAs, the ‘guide’ strand with a prevalence of 
96–99% and higher biological activity and the ‘passenger’ miRNA* strand. [9]  
 
MiRNA strand selection depends on different factors including the thermodynamic stability at the 
ends of the miRNA:miRNA* duplex. [38, 39] Though the miRNA* strand is usually degraded, in 
some cases both strands can be functional [39] with either overlapping or different target sites. [40] 
MiRNA*-sequences are likely to have functional relevance in small RNA regulatory networks, as 
they are highly evolutionary conserved with e.g. more than 40% of miRNA*-sequences resisting 
nucleotide divergence across Drosophila evolution. [41] Given that both the ‘mature’ and the 
‘passenger’ strands can be functional, the miRNA/miRNA* nomenclature has now been retired and 
instead the two sequences are referred to as 5-p or 3-p strand of the respective miRNA. 
 
Once they have bound to their target mRNA, miRNAs are able to regulate gene expression in 
different and sometimes opposite ways depending on factors like the amount of complementarity with 
the target mRNA.  Near-perfect complementarity of miRNAs and their targets which mainly occurs in 
plants, leads to direct cleavage of the target mRNA. [42]  In animals, however, target recognition in 
most cases does not require perfect complementarity but mainly depends on pairing to the “miRNA 
seed”, the nucleotides 2-8 of the 5’ portion of the miRNA. [43] The short seed match and incomplete 
base pairing enable the miRNA to target different RNA molecules while a single target gene can 
contain multiple conserved regions of complementarity. [43] [44] 
 
The predominant mechanism by which miRNAs reduce protein output is by triggering deadenylation 
of the target mRNA, which makes the mRNA more susceptible to degradation. [45] Additionally 
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miRNAs can inhibit eukaryotic initiation factors [46] or interfere with translational elongation [47]. In 
some cases the miRNA response can switch from inhibition of gene expression to enhancement 
thereby e.g. inducing up-regulation of target mRNAs on cell cycle arrest and repressing translation in 
proliferating cells. [48] [4] 
 
These characteristics create a complex regulatory control network that changes in relation to age, 
developmental or pathophysiological state of the cell, and involves multiple co-operative effects on a 
large number of targets enabling miRNAs to control various pathways at different levels. [49] 
 
 
 
 
 
Figure 2 Schematic diagram of proposed mechanisms for miRNA function. (A) Ago-mediated cleavage of 
mRNA can occur when the miRNA sequence is complementary to the target gene-binding site. (B) 
Removal of poly(A) tail by deadenylases causes destabilization and degradation of mRNA. (C) Translation 
initiation inhibited by miRISC interactions with eukaryotic translation initiation factors (eIFs). (D) 
Inhibition of translation postinitiation. (E) Sequestration of mRNA in P-bodies. (F) miRNA-mediated 
translational activation. Taken from [4] 
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1.5. MiRNAs in Circulation: 
The majority of miRNAs are located intracellularly. In 2007, however, miRNAs were found in 
exosomes, in which they were delivered to other cells allowing gene-based communication between 
cells. [50] Sequence motifs present in miRNAs can thereby enable specific interaction and loading 
into exosomes. [51] This transfer of RNA through exosomes may enable local and systemic 
intercellular exchange of biological information in a way similar to hormones. [50] In the following 
years, miRNAs were detected in most extracellular biological fluids including serum, plasma, saliva 
or urine where they showed distinct compositions. [52] 
 
MiRNAs can be released into the blood circulation by various physiological mechanisms, including 
active secretion, apoptosis or necrosis. These miRNAs circulate in different types of vesicles, such as 
apoptotic bodies, microvesicles (100–1000 nm), and exosomes (50–100 nm). [53] Many extracellular 
miRNAs in circulation, however, are also independent of vesicles and are associated with RNA-
binding proteins like Argonaute 2 protein, a part of the RNA-induced silencing complex. [54] 
 
 
 
Figure 3 Mechanisms of miRNA release from cells into peripheral blood circulation and transport to target 
cells. MP: microparticles; HDL: high-density lipoprotein; Ago2: Argonaute 2. Taken from [14] 
 
Human miRNAs isolated from plasma are highly stable in boiling water and resistant to very high or 
low pH, prolonged room temperature incubation or repeated freeze-thawing. [55] Compared to 
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endogenous plasma miRNAs, synthetic miRNAs are rapidly degraded when added to human plasma 
unless the RNase activity was inactivated beforehand. [56] Therefore, though miRNAs are susceptible 
to rapid degradation, circulating miRNAs are stable and resistant to RNase activity as they are 
secreted in a complex with other molecules such as Argonaute proteins or lipoproteins or in 
membrane derived vesicles. [55]  
 
1.6. MiRNAs as Biomarkers: 
Deregulated levels of circulating miRNAs have been linked to different disease states. [26] During 
cellular stress or pathophysiological conditions such as hypoxia, miRNAs can provide an efficient 
way of gene regulation to allow the cells to adopt and recover. [57]  As they are disease-specifically 
modulated and easily accessible, circulating miRNAs are potential blood-based biomarkers, useful for 
diagnostic application e.g. in screening programs and for monitoring of treatment response or 
outcome prediction. [4] [53] 
 
Based on their biology, circulating miRNAs can have a high level of sensitivity and specificity 
allowing early and reliable detection of pathological states. [49] Arguably, miRNAs offer some 
advantages over the most commonly used protein biomarkers: They interact with their target through 
Watson-Crick base pairing, a more predictable and stable interaction than processes involving for 
example proteins or lipids. [58] In addition miRNA are often expressed in a tissue-, development- or 
disease-specific manner and the levels of miRNAs in serum are reproducible and consistent among 
individuals of the same species. [53] [59] 
  
Compared to numerous serum proteins, including various processing variants, and posttranslationally 
modified proteins, there are far fewer known miRNA species, making it possible to obtain a 
comprehensive profile. MiRNAs themselves reflect altered physiology more directly, as unlike 
proteins, which must be translated from mRNA to have a biological effect, they exert their effects 
directly. In addition, due to their small size, chemical composition and limited posttranslational 
modifications, miRNAs are much less complex than most other biological molecules and more stable 
in plasma than other RNAs such as mRNAs. [59] Also, miRNAs can be quantified cost-effectively 
using real-time polymerase chain reaction or microarrays and a comprehensive profile can be obtained 
by next generation sequencing.  
 
An example for the potential use of miRNAs as biomarkers is the detection of myocardial infarction, 
where they might complement the existing biomarkers, such as cardiac troponins. There is still a need 
for novel biomarkers, as troponins fail to rule out myocardial infarction immediately on admission 
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and are not reliable in certain groups of patients. [55] [53] This is mainly due to their limited 
sensitivity, as their plasma levels do not change unless there is substantial damage in the heart, 
presenting low serum concentrations early after infarction and especially in geriatric patients often 
generally insufficient elevation for reliable diagnosis. Another major limitation is their lack of 
specificity, as unspecific elevation of troponin levels can be caused by non-ischemic conditions such 
as heart failure and renal disease. [60] 
 
MiRNAs that are specifically expressed in the heart muscle, like miR-208a, which is involved in the 
regulation of  myosin heavy chain production during cardiac development [16], have the potential to 
improve diagnosis of myocardial infarction as they might show greater sensitivity and specificity than 
existing biomarkers.  
 
In a study with 33 consecutive AMI and 33 non-AMI patients that presented with chest pain, miR-
208a remained undetectable in plasma of non-AMI patients including patients with chronic renal 
failure or trauma, but it was initially detected in 90.9% of AMI patients and in 100% of AMI patients 
within 4 h of the onset of chest pain, even in patients where cTnI levels were not yet affected. This 
earlier miRNA peak might be caused by a faster release of miRNAs from damaged cardiomyocytes, 
as miRNAs are mainly bound to protein complexes in the cytosol while most of the cTnI is bound to 
myofibrils. [61] [62] On the other hand, potential confounding factors of miRNA measurements 
remain be characterised to assess the clinical utility of miRNA biomarkers.  
 
 
1.7. Summary of Publications: 
 
MiRNAs are already beginning to be used therapeutically, like miravirsen, an antisense inhibitor of 
miR-122, which has been successfully tested in phase-II trials for the treatment of hepatitis C virus 
infection. [63] Nevertheless the only example where circulating nucleic acids are used as biomarkers 
so far is in non-invasive prenatal diagnosis. [64] [53] Apart from the lack of large cohort studies, 
miRNA measurements are hampered by the limited knowledge about confounding factors. Circulating 
levels of miRNAs have been measured in various studies related to cardiovascular disease but the 
effect of medication, commonly used in cardiovascular patients, specifically the effect of antiplatelet 
therapy and heparin administration, is unclear. This was addressed in the present thesis: 
 
Effect of anti-platelet medication: 
Antiplatelet therapy is widely used in prevention and treatment of cardiovascular disease. The study 
by Willeit and Zampetaki et al (Circ Res 2013) identified circulating platelet miRNAs that are 
responsive to antiplatelet therapy. In healthy volunteers, prolonged platelet inhibition over 4 weeks 
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affected the levels of circulating miRNAs and resulted in a reduction of several miRNAs, including 
miR-126 (P<0.001), miR-150 (P=0.003), miR-191 (P=0.004), and miR-223 (P=0.016). Similar 
results were obtained in patients with symptomatic carotid atherosclerosis (n=33) who were on 75 mg 
aspirin (ASA) at baseline. After initiation of dual antiplatelet therapy with either dipyridamole or 
clopidogrel miRNA changes were observed after 48 h. Although the miRNA content of platelets is 
low compared with other cells, platelets contribute substantially to the circulating miRNA pool. 
Antiplatelet therapy was therefore a likely confounding factor in previous case–control studies 
reporting a loss of miRNAs in patients with coronary artery disease. [65] 
 
Effect of heparin: 
Heparin, used in interventional cardiology, is another potential confounding factor that may influence 
miRNA measurements due to its known interference with polymerase chain reactions. [66] [67] In the 
study by Kaudewitz et al (Thromb Haemost 2013), platelet-poor plasma was obtained from patients 
undergoing cardiac catheterisation for diagnostic coronary angiography, or for percutaneous coronary 
intervention, both before and after heparin administration. Heparin had pronounced effects on the 
assessment of the exogenous C. elegans spike-in control (decrease by approx. 3 cycles), which 
disappeared 6 hours after the heparin bolus. Measurements of endogenous miRNAs were less 
sensitive to heparin medication. Normalisation of individual microRNAs with the average cycle 
threshold value of all microRNAs provided a suitable alternative to normalisation with exogenous C. 
elegans spike-in control in this setting. Thus, both the timing of blood sampling relative to heparin 
dosing and the normalisation procedure are critical for reliable miRNA measurements in patients 
receiving intravenous heparin.  
 
In summary, both anti-platelet and heparin medication are confounding factors for miRNA 
measurements, which have to be taken into account when investigating the relation of circulating 
miRNAs with cardiovascular disease. As this limitation has not been previously recognised, a re-
evaluation of the current miRNA literature, in particular of case-control studies in patients with 
cardiovascular disease or coronary interventions, is required. Future studies will need to address these 
shortcomings of the early literature on miRNA biomarkers. 
 
 
1.8. Zusammenfassung der Publikationen: 
MiRNAs werden mittlerweile bereits in ihrer therapeutischen Anwendung getestet, so z.B. miravirsen, 
ein miR-122-Antisense-Inhibitor, der erfolgreich in Phase-II-Studien in der Behandlung von Hepatitis 
C eingesetzt wurde. [63] Dennoch ist die Pränataldiagnostik bisher das einzige Beispiel für die 
 10  
 
Anwendung zirkulierender Nukleinsäuren als Biomarker. [64] [53] Ursache dafür sind nicht nur der 
Mangel an hinreichend großen Kohorten-Studien, sondern auch begrenzte Kenntnisse über 
Störfaktoren, die miRNA-Messungen beeinflussen. 
Expressionsmuster zirkulierender miRNAs, die spezifisch für kardiovaskuläre Erkrankungen sind, 
wurden bereits in zahlreichen Biomarker-Studien untersucht. Der Effekt von Medikamenten, die 
häufig bei kardiovaskulären Patienten eingesetzt werden, insbesondere von Thrombozyten- 
aggregationshemmern und Heparin ist jedoch bislang unbekannt. 
Der Einfluss dieser Medikamente wurde in der vorliegenden Arbeit untersucht. 
 
Effekt der Thrombozytenaggregationshemmer: 
Der Einsatz von Thrombozytenaggregationshemmern ist weit verbreitet in der Prävention und 
Behandlung kardiovaskulärer Erkrankungen. Die Studie von Willeit und Zampetaki et al (Circ Res 
2013) identifizierte zirkulierende Thrombozyten-miRNAs, die durch Thrombozyteninhibition 
beeinflusst werden. In gesunden Probanden beeinflusste die Einnahme von Thrombozyten-
aggregationshemmern über einen Zeitraum von 4 Wochen die Spiegel zirkulierender miRNAs im Blut 
und führten zu einer Reduktion der Spiegel mehrerer miRNAs, einschließlich miR-126 (P<0.001), 
miR-150 (P=0.003), miR-191 (P=0.004) und miR-223 (P=0.016). Ähnliche Ergebnisse wurden in 
Patienten mit symptomatischer Karotisstenose beobachtet, die bereits zu Beginn der Studie 75 mg 
Aspirin (ASA) einnahmen. Nach Beginn einer dualen Antiplättchen-Therapie entweder mit 
Dipyridamol oder Clopidogrel wurde die Veränderung der miRNA-Spiegel nach 48 Stunden 
gemessen. Obwohl der miRNA-Gehalt von Thrombozyten im Vergleich zu anderen Zellen niedrig ist, 
tragen Thrombozyten wesentlich zum zirkulierenden miRNA-Pool bei. Gerinnungshemmende 
Medikamente stellen daher wahrscheinlich Störfaktoren in früheren Fall-Kontroll-Studien dar, die 
über eine Reduktion der miRNA-Spiegel bei Patienten mit koronarer Herzkrankheit berichten. [65] 
 
Effekt von Heparin: 
Heparin, das in der interventionellen Kardiologie eingesetzt wird, ist ein weiterer potentieller 
Störfaktor für miRNA-Messungen aufgrund seiner bereits bekannten Interferenz mit Polymerase-
Kettenreaktionen. [66] [67] In der Studie von Kaudewitz et al (Thromb Haemost 2013) wurde 
thrombozytenarmes Plasma von Patienten, bei denen ein Herzkatheter gelegt wurde, um eine 
Koronarangiographie oder perkutane Koronarintervention durchzuführen, vor und nach Heparin-Gabe 
untersucht. Die Anwendung von Heparin hatte deutliche Auswirkungen auf die Messung der 
exogenen C. elegans Spike-in-Kontrolle (Rückgang um ca. 3 Zyklen), die 6 Stunden nach dem 
Heparin-Bolus verschwanden. Messungen endogener miRNAs zeigten sich weniger empfindlich 
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gegenüber der Anwendung von Heparin. Normalisierung der einzelnen miRNAs mit dem 
durchschnittlichen Zyklus-Schwellenwert aller miRNAs stellte eine geeignete Alternative zu einer 
Normalisierung mit exogener C. elegans Spike-in-Kontrolle in diesem Zusammenhang dar. Somit 
sind sowohl der Zeitpunkt der Blutentnahme relativ zur Verabreichung von Heparin und die 
Anwendung des geeigneten Normalisierungsverfahrens entscheidend für zuverlässige miRNA-
Messungen bei Patienten, die Heparin intravenös erhalten.   
 
Zusammenfassend sind sowohl die Gabe von Thrombozytenaggregationshemmern als auch von 
Heparin Störfaktoren bei miRNA-Messungen, die bei der Untersuchung von zirkulierenden miRNAs 
bei kardiovaskulären Erkrankungen in künftigen Studien und bei der Bewertung der bisherigen 
Literatur berücksichtigt werden sollten.  
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1.9. Abbreviations: 
 
Ago   Argonaute 
AMI   acute myocardial infarction 
C.elegans  Caenorhabditis elegans 
cTnI   cardiac Troponin I 
DGCR8  DiGeorge critical region 8  
miRNA   microRNA 
mRNA   messenger RNA 
PACT   protein activator of the interferon-induced protein kinase 
Ran-GTP  Ras-related nuclear protein-Guanosine triphosphate 
RISC   RNA-induced silencing complex 
RNase   ribonuclease 
TRBP transactivation response RNA binding protein 
tRNA   transfer RNA 
UTR   untranslated region 
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